{
  "id": 1769622318698,
  "seqId": 163,
  "title": "Comprehensive Clinical Guide to Dry Eye Disease (DEWS II)",
  "summary": "An exhaustive clinical resource detailng the TFOS DEWS II definition, diagnostic classification, and staged management of dry eye disease. This guide covers everything from homeostatic markers and scoring patient-reported outcomes to the four-step treatment algorithm.",
  "date": "2026-01-28T17:45:18.698Z",
  "data": {
    "title": "Comprehensive Clinical Guide to Dry Eye Disease (DEWS II)",
    "summary": "An exhaustive clinical resource detailng the TFOS DEWS II definition, diagnostic classification, and staged management of dry eye disease. This guide covers everything from homeostatic markers and scoring patient-reported outcomes to the four-step treatment algorithm.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><path d='M10 50 Q50 10 90 50 Q50 90 10 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='3'/><circle cx='50' cy='50' r='15' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M50 50 Q55 65 50 75 Q45 65 50 50' fill='hsl(200, 80%, 60%)'/></svg>",
    "sections": [
      {
        "title": "Defining Dry Eye: The TFOS DEWS II Framework",
        "icon": "biotech",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "Dry Eye (Syn KCs)",
          "branches": [
            "Definition: Multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film.",
            "Core Etiologies: Tear film instability, Hyperosmolarity, Ocular surface inflammation and damage, Neurosensory abnormalities.",
            "Symptoms: Accompanied by ocular symptoms.",
            "Severity: May be severe, very painful, and vision-threatening.",
            "Common Misdiagnosis: Patients often describe mild tear film instability associated with blepharitis or MGD as 'dry eyes'—treatment should focus on blepharitis in these cases."
          ]
        }
      },
      {
        "title": "Clinical Features & Pathophysiology",
        "icon": "visibility",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "purple",
        "content": "Symptoms are 2° to a combination of decreased lubrication (rapid tear film break-up, increased mechanical shear stresses between the lids and globe, reduced expression of mucins) and alteration of tear film composition (hyperosmolarity, inflammatory mediators), together with hypersensitivity of the nociceptive sensory nerves of the ocular surface."
      },
      {
        "title": "Key Symptoms and Signs",
        "icon": "list",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Burning (may be very painful)",
          "Itching",
          "Blurred vision (indicates corneal involvement)",
          "Mucus strands",
          "Small or absent concave tear meniscus",
          "Punctate epitheliopathy",
          "Filaments",
          "Mucus plaques",
          "TBUT < 10s",
          "Lissamine green <o> pattern",
          "Schirmer test < 5mm over 5min (without topical anaesthetic)",
          "Note: Symptoms may outweigh signs, and vice versa."
        ]
      },
      {
        "title": "Table 6.5: Major Causes of Dry Eyes",
        "icon": "clinical_notes",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Aqueous-Deficient",
            "Evaporative (Intrinsic/Extrinsic)"
          ],
          "rows": [
            [
              "Sjögren's Syndrome: 1° (KCs with xerostomia) and 2° (KCs with xerostomia + connective tissue disease like RA, SLE, Systemic Sclerosis, GVHD).",
              "Intrinsic (Direct effect): Meibomian oil deficiency, Lid aperture problems, Low blink rate, Drugs."
            ],
            [
              "Lacrimal Gland Deficiencies: 1° (Age-related, Congenital alacrima, Familial dysautonomia) and 2° (Sarcoidosis, Lymphoma, AIDS, GVHD, Ablation, Denervation).",
              "Extrinsic (Indirect effect): Vitamin A deficiency, Topical drugs/preservatives, CL wear, Ocular surface disease (e.g. allergies), MGD."
            ],
            [
              "Lacrimal Gland Duct Obstruction: Trachoma, OCMMP, Erythema multiforme, Chemical and thermal burns.",
              ""
            ],
            [
              "Reflex Hyposecretion: Reflex sensory block (CL wear, Diabetes, Neurotrophic keratitis), Reflex motor block (VII damage, Multiple neuromatosis).",
              ""
            ],
            [
              "Systemic Drugs.",
              ""
            ]
          ]
        }
      },
      {
        "title": "Figure 6.3: DEWS II Classification Flowchart",
        "icon": "account_tree",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Patient Status",
            "Signs of OSD",
            "No Signs of OSD",
            "Management Direction"
          ],
          "rows": [
            [
              "Asymptomatic",
              "Signs indicate predisposition or Neurotrophic conditions",
              "Normal",
              "No treatment vs Preventative (pre-surgery) vs Observe"
            ],
            [
              "Symptomatic",
              "Signs present (DED)",
              "No Signs (Pre-clinical or Neuropathic pain)",
              "Differential Diagnosis vs Pain Management vs Restore Homeostasis"
            ],
            [
              "Dry Eye Disease Spectrum",
              "Aqueous deficient",
              "Mixed",
              "Evaporative"
            ]
          ]
        }
      },
      {
        "title": "Diagnostic Approach (Fig 6.4)",
        "icon": "query_stats",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "START: Triaging Questions",
          "Risk Factor Analysis",
          "Screening for Suspect Dry Eye",
          "Homeostasis Markers: Osmolarity, Ocular Surface Staining, TMH",
          "Subtype Classification: Aqueous Deficiency vs Evaporative Spectrum"
        ]
      },
      {
        "title": "Patient-Reported Outcomes (PROs)",
        "icon": "history_edu",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Global public health problem impacting visual function, work, and general health.",
          "Ocular Surface Disease Index (OSDI): 12-item questionnaire (Visual function: 6, Ocular symptoms: 3, Environmental triggers: 3). Scale 0 (no disability) to 100 (complete disability).",
          "Dry Eye Questionnaire (DEQ-5): Shorter 5-item version.",
          "Symptom Assessment iN Dry Eye (SANDE): 2-item frequency and severity-based visual analog scale for daily diary use."
        ]
      },
      {
        "title": "Scoring Ocular Surface Staining (SICCA OSS)",
        "icon": "format_list_numbered",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Zone",
            "Grade 0 (Dots)",
            "Grade 1 (Dots)",
            "Grade 2 (Dots)",
            "Grade 3 (Dots)"
          ],
          "rows": [
            [
              "Conjunctiva (Lissamine Green)",
              "0-9",
              "10-32",
              "33-100",
              "> 100"
            ],
            [
              "Cornea (Fluorescein)",
              "0",
              "1-5",
              "6-30",
              "> 30"
            ],
            [
              "Extra Points (Fluorescein Only)",
              "Weighting for confluent staining, pupillary area staining, and presence of filaments.",
              "Max Score: 12 per eye.",
              "",
              ""
            ]
          ]
        }
      },
      {
        "title": "Table 6.6: TFOS DEWS II Staged Management Algorithm",
        "icon": "medical_services",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Step",
            "Recommendations"
          ],
          "rows": [
            [
              "Step 1",
              "Education on condition/prognosis; modification of local environment; dietary modification (Essential Fatty Acid supplementation); eliminate offending medications; ocular lubricants (lipid-containing for MGD); lid hygiene and warm compresses."
            ],
            [
              "Step 2",
              "Non-preserved ocular lubricants; tea tree oil (for Demodex); tear conservation (punctal plugs, moisture chamber goggles); overnight ointments/moisture devices; physical MG heating/expression (e.g., Lipiflow, IPL); Prescription drugs: topical antibiotic/steroid for lids, limited topical corticosteroid, secretagogues, non-glucocorticoid immunomodulators (ciclosporin), LFA-1 antagonist drugs, oral macrolides/tetracyclines."
            ],
            [
              "Step 3",
              "Oral secretagogues; Autologous and allogeneic serum eye drops; therapeutic CL options (soft BCLs, rigid scleral CLs)."
            ],
            [
              "Step 4",
              "Long-duration topical corticosteroids (monitor RNFL/VFs); Amniotic membrane grafts; Surgical punctal occlusion; Tarsorrhaphy; Salivary gland transplantation."
            ]
          ]
        }
      },
      {
        "title": "Practicalities: Lubricants & Conservation",
        "icon": "science",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": [
          "Conservative: Cool mist humidifiers, Lid hygiene, Omega-3/7 supplementation, Moist-chamber goggles (reduce evaporation by 30%).",
          "Viscosity: Low (frequent use, minimal blur) vs Viscous gels (4-6x/day, transient blur) vs Paraffin-based ointments (Night use, significant blur).",
          "Preservative-Free: Essential if used > 6x/day to reduce epithelial toxicity.",
          "Hyaluronic Acid: Natural component, cytoprotective, improves surface retention by binding to CD44 in inflamed eyes.",
          "Carmellose (CMC): Cytoprotective and lubricating agent.",
          "Basic lubricants: Hypromellose, carmellose, carbomer gels.",
          "Advanced lubricants: Hydroxypropylguar, hyaluronates, osmoprotectants (polysaccharides), xanthan gum, soybean with phospholipids."
        ]
      },
      {
        "title": "Tear and Surface Modification",
        "icon": "healing",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Tear Modification: Acetylcysteine 5% 4x/d (warn about stinging) for filaments or mucus plaques.",
          "Tear Stimulation: Pilocarpine hydrochloride 2.5mg 1-4x/d for Sjögren’s (if residual function exists). Maximize to 5mg/d or use 4% drops (3 drops = 6mg).",
          "Punctal Occlusion: Collagen (temporary) or Silicone (permanent) plugs. Permanent via cautery or suture. NB: Delay until inflammation is treated to avoid retaining pro-inflammatory tear constituents.",
          "Surface Modification: Silicone hydrogel or Scleral CLs. Surgery: Salivary gland transposition (risk of gustatory epiphora)."
        ]
      },
      {
        "title": "Advanced Disease Modification",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Topical anti-inflammatories: Glucocorticoids (PF), Calcineurin inhibitors.",
          "Ciclosporin 0.1% (Ikervis): Typically for corneal consultants only.",
          "Systemic MMP inhibitors: Doxycycline 50–100mg for minimum 3 months.",
          "Low-dose Doxycycline (Periostat 20mg): Long-term for those intolerant to 50mg.",
          "Serum Eye Drops: Reserved for severe cases when licensed options fail. Available as autologous or allogeneic (via NHSBT in UK)."
        ]
      },
      {
        "title": "References & Footnotes",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "10 Craig JP et al. TFOS DEWS II Definition and Classification report. Ocul Surf. 2017;15:276–83. 11 Wolffsohn JS et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539–74. 12 Whitcher JP et al. SICCA Ocular staining score. Am J Ophthalmol. 2010;149:405–15. 13 Bron AJ et al. Oxford scheme. Cornea. 2003;22:640–50. 14 Jones L et al. TFOS DEWS II Management and therapy report. Ocul Surf. 2017;15:575–628. 16 NICE [TA369] Ciclosporin. 17 Rauz S et al. RCOphth guidelines on serum eye drops. Eye (Lond). 2017."
      }
    ],
    "chapterId": "cornea"
  },
  "chapterId": "medical_retina",
  "_newlyImported": 1769622318698,
  "communityId": "sub_1769618268159_h2xpztga7kfg4b",
  "communityAuthor": "Dodiii",
  "communityDate": "2026-01-28T16:37:48.159Z",
  "_serverSynced": true
}